Tiziana Life Sciences Ltd - Company Profile
Powered by 
All the sales intelligence you need on Tiziana Life Sciences Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Tiziana Life Sciences Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Tiziana Life Sciences Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Tiziana Life Sciences Ltd (Tiziana) is focused on developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drugs targeting Secondary Progressive Multiple Sclerosis (SPMS), Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and KRAS-positive non-small cell lung cancer (NSCLC). Tiziana's lead product candidate, Foralumab, is a fully human anti-CD3 monoclonal antibody in clinical development for neurodegenerative diseases and Crohn’s disease. Tiziana in-licensed the intellectual property for Foralumab from Novimmune.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer